Desh Rakshak

Why is Desh Rakshak Aushdhalaya Ltd falling/rising?

As of 01-Sep, the stock price of Desh Rakshak Aushdhalaya Ltd is at 26.90, showing a -13.23% decline over the past month, underperforming the Sensex. The company's weak financial health, characterized by declining net sales and low profitability, contributes to a negative outlook for the stock.

As of 01-Sep, the stock price of Desh Rakshak Aushdhalaya Ltd is currently at 26.90, with no change from the previous trading session. The stock has shown a performance of -13.23% over the past month, while the benchmark Sensex has only declined by 1.47% in the same period. This indicates that the stock is underperforming relative to the market.<BR><BR>Despite a slight outperformance today against its sector by 0.6%, the stock has exhibited erratic trading patterns, having not traded on 5 out of the last 20 days. Furthermore, while there has been a notable increase in delivery volume, rising by 600% on 13 August compared to the 5-day average, this may not be sufficient to offset the overall negative sentiment surrounding the stock.<BR><BR>The company's financial health is concerning, with a weak long-term fundamental strength reflected in a -0.97% CAGR growth in net sales over the last five years and a poor EBIT to interest ratio of 0.96, indicating difficulties in servicing its debt. Additionally, the company's return on equity stands at a low 5.25%, suggesting low profitability per unit of shareholders' funds. The most recent financial results show a significant decline in net sales, down by 24.97%, and the lowest recorded return on capital employed at 6.03%.<BR><BR>In summary, the combination of poor financial performance, weak growth metrics, and underperformance relative to the market contributes to the stock's current stagnation and negative outlook.

Who are in the management team of Desh Rakshak?

The management team of Desh Rakshak includes Tosh Kumar Jain (Chairman & Managing Director), Monika Jain and Arihant Kumar Jain (Whole-time Directors), Mohit Kumar (Independent Director), Sohini Bansal (Company Secretary & Compliance Officer), and Shruti Gupta (Additional Director).

The management team of Desh Rakshak includes the following individuals:<BR><BR>1. **Tosh Kumar Jain** - Chairman & Managing Director<BR>2. **Monika Jain** - Whole-time Director<BR>3. **Arihant Kumar Jain** - Whole-time Director<BR>4. **Mohit Kumar** - Independent Director<BR>5. **Sohini Bansal** - Company Secretary & Compliance Officer<BR>6. **Shruti Gupta** - Additional Director<BR><BR>If you need more information about their roles or the company, feel free to ask!

What does Desh Rakshak do?

Desh Rakshak Aushdhalaya Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology sector, focusing on Ayurvedic and herbal products. As of June 2026, it reported net sales of 1 Cr and a market cap of INR 15 Cr.

Overview: <BR>Desh Rakshak Aushdhalaya Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, specializing in the manufacture of pure Ayurvedic and herbal products.<BR><BR>History: <BR>The company was originally established in 1901 as a proprietorship by Shri Bhagwant Rai Jain and was converted into a Private Limited Company in July 1994. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 15 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 28.00 <BR>Industry P/E: 27 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.20 <BR>Return on Equity: 4.29% <BR>Price to Book: 1.15 <BR><BR>Contact Details: <BR>Address: Bhagwant Kuti, Kankhal Haridwar UTT : 249408 <BR>Tel: 91-1334-243833 <BR>Email: daral96@yahoo.in/dral95@yahoo.com <BR>Website: http://www.deshrakshak.com

Who are the peers of the Desh Rakshak?

Peers of Desh Rakshak include Colinz Labs, Bacil Pharma, Zenith Health, Dipna Pharmachem, Starsource Multi, Ortin Global, Beryl Drugs, Mono Pharmacare, and Saroja Pharma In. Management risk is generally below average for most peers, with varying growth and capital structure ratings, while Desh Rakshak's 1-year return is not available for comparison.

Peers: The peers of Desh Rakshak are Colinz Labs, Bacil Pharma, Zenith Health, Dipna Pharmachem, Starsource Multi, Ortin Global, Beryl Drugs, Mono Pharmacare, and Saroja Pharma In.<BR><BR>Quality Snapshot: Below Average management risk is observed at Colinz Labs, Zenith Health, Dipna Pharmachem, Ortin Global, Beryl Drugs, Mono Pharmacare, and Saroja Pharma In, while Average management risk is found at Saroja Pharma In. Bacil Pharma and Starsource Multi do not qualify for management risk assessment. Excellent growth is noted at Dipna Pharmachem, while Below Average growth is seen at Colinz Labs, Zenith Health, Desh Rakshak, Ortin Global, Beryl Drugs, Mono Pharmacare, and Saroja Pharma In, with Bacil Pharma and Starsource Multi not qualifying. Capital Structure is rated as Good for Colinz Labs and Zenith Health, while Below Average is observed at Desh Rakshak, Dipna Pharmachem, Ortin Global, Beryl Drugs, Mono Pharmacare, and Saroja Pharma In, with Bacil Pharma and Starsource Multi not qualifying.<BR><BR>Return Snapshot: Colinz Labs has the highest 1-year return at 80.21%, while Dipna Pharmachem has the lowest at -73.42%. Desh Rakshak's 1-year return is not available for comparison. Additionally, the six-month return is negative for Dipna Pharmachem, Starsource Multi, and Beryl Drugs.

How big is Desh Rakshak?

As of 31st August, Desh Rakshak Aushdhalaya Ltd has a market capitalization of 15.00 Cr, with recent Net Sales of 6.63 Cr and a Net Profit of 0.55 Cr.

As of 31st August, Desh Rakshak Aushdhalaya Ltd has a market capitalization of 15.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Desh Rakshak reported Net Sales of 6.63 Cr and a Net Profit of 0.55 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 9.96 Cr and Total Assets of 17.98 Cr.

Which are the latest news on Desh Rakshak?

Should I buy, sell or hold Desh Rakshak Aushdhalaya Ltd?

Are Desh Rakshak Aushdhalaya Ltd latest results good or bad?

Desh Rakshak Aushdhalaya Ltd's latest results show strong profitability with a 233.33% increase in net profit and improved operating margins, but a 21.41% year-on-year revenue decline raises concerns about sustained growth. Overall, the results are good for profitability but bad for revenue performance.

Desh Rakshak Aushdhalaya Ltd's latest results present a mixed picture. In Q4 FY26, the company reported a net profit of ₹0.30 crores, which is a significant increase of 233.33% compared to the previous quarter. This indicates a strong sequential recovery in profitability. Additionally, the operating margin improved to 17.97%, up from 15.43% in the same quarter last year, suggesting better cost management.<BR><BR>However, the revenue figures tell a different story. The company generated ₹3.45 crores in revenue for Q4 FY26, which reflects a dramatic 146.43% increase from ₹1.40 crores in Q3 FY26. Despite this impressive quarter-on-quarter growth, the year-on-year comparison shows a decline of 21.41% from ₹4.39 crores in Q4 FY25, indicating ongoing demand challenges in its core Ayurvedic product portfolio.<BR><BR>Overall, while there are positive signs in terms of profitability and margin expansion, the significant year-on-year revenue decline raises concerns about the company's ability to sustain growth. Therefore, the results can be viewed as good in terms of profitability but bad regarding revenue performance.

When is the next results date for Desh Rakshak Aushdhalaya Ltd?

The next results date for Desh Rakshak Aushdhalaya Ltd is 29 May 2026.

The next results date for Desh Rakshak Aushdhalaya Ltd is scheduled for 29 May 2026.

Is Desh Rakshak overvalued or undervalued?

As of November 21, 2025, Desh Rakshak is fairly valued with a PE ratio of 37.17 and an EV to EBITDA of 14.92, showing strong performance compared to peers like Sun Pharma and Cipla, despite recent stock volatility and a YTD return of 159.81%.

As of 21 November 2025, Desh Rakshak's valuation grade has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently fairly valued, with a PE ratio of 37.17, an EV to EBITDA of 14.92, and a Price to Book Value of 1.90. In comparison to its peers, Sun Pharma has a PE ratio of 36.98 and an EV to EBITDA of 24.43, while Cipla stands out as attractive with a PE ratio of 22.45 and an EV to EBITDA of 15.88.<BR><BR>Despite the recent volatility in its stock price, which has seen a significant YTD return of 159.81% compared to the Sensex's 9.08%, the company's valuation metrics suggest it is well-positioned within the pharmaceuticals and biotechnology sector. Overall, Desh Rakshak appears to be fairly valued in the current market environment.

How has been the historical performance of Desh Rakshak?

Desh Rakshak's historical performance shows a mixed trend, with net sales increasing slightly to 6.27 Cr in Mar'25, stable operating profit, and improved profits before and after tax. Despite rising total liabilities, the company has demonstrated resilience with gradual improvements in profitability and sales.

Answer:<BR>The historical performance of Desh Rakshak shows a mixed trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Desh Rakshak's net sales have shown a slight increase from 6.01 Cr in Mar'24 to 6.27 Cr in Mar'25, following a peak of 6.60 Cr in Mar'21. The total operating income also reflects this trend, reaching 6.27 Cr in Mar'25. The total expenditure, excluding depreciation, increased from 4.73 Cr in Mar'24 to 5.02 Cr in Mar'25. Operating profit (PBDIT) has remained relatively stable, with a slight decrease from 1.30 Cr in Mar'24 to 1.28 Cr in Mar'25. Profit before tax improved from 0.51 Cr in Mar'24 to 0.56 Cr in Mar'25, while profit after tax rose from 0.43 Cr to 0.48 Cr in the same period. The earnings per share (EPS) increased from 0.97 in Mar'24 to 1.08 in Mar'25. On the balance sheet, total liabilities increased from 15.74 Cr in Mar'23 to 16.32 Cr in Mar'24, with total assets also rising to 16.32 Cr. The cash flow from operating activities showed a positive change, with 1.00 Cr reported in Mar'24, while cash flow from investing activities remained negative at -1.00 Cr in Mar'22 and Mar'21. Overall, Desh Rakshak has demonstrated resilience in its financial performance, with gradual improvements in profitability and sales despite fluctuations in expenses and liabilities.

Who are the top shareholders of the Desh Rakshak?

The top shareholders of Desh Rakshak include promoters, with Tosh Kumar Jain holding 28.2% of the shares, and individual investors owning 35.58%. There are no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Desh Rakshak primarily include the promoters, with Tosh Kumar Jain holding the highest stake at 28.2%. Additionally, individual investors collectively own 35.58% of the company's shares. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company, and there are no pledged promoter holdings.

What is the technical trend for Desh Rakshak?

As of May 29, 2025, Desh Rakshak's technical trend is mildly bullish, supported by bullish MACD and moving averages, despite some bearish signals from the RSI and KST.

As of 29 May 2025, the technical trend for Desh Rakshak has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish, indicating positive momentum. However, the weekly RSI is bearish, suggesting some weakness in the short term. Bollinger Bands show a mildly bullish stance on both weekly and monthly time frames, supporting the overall mildly bullish trend. Daily moving averages are bullish, reinforcing the positive outlook. The KST indicates a mildly bearish trend on the weekly, but bullish on the monthly, which adds mixed signals. Dow Theory shows a mildly bearish trend on the weekly, with no trend on the monthly. Overall, the technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some bearish signals from the RSI and KST.

Has Desh Rakshak declared dividend?

No Dividend History Available